World game at war: why some European nations have threatened a World Cup boycott 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
| Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) | |||||||
| Annual General Shareholders' Meeting of May 2, 2018 Shareholders' approval of the financial statements for 2017 Dividend of €3.03 per share payable as of May 15, 2018 Board Composition: renewals and appointment Paris (France) - May 2, 2018 - The Combined General Shareholders' Meeting of Sanofi was held today at the Palais des Congrès in Paris under the chairmanship of Serge Weinberg. All resolutions submitted to the vote were adopted by its shareholders. The shareholders approved, among other resolutions, the individual Company and consolidated financial statements for the year 2017. At the General Meeting, shareholders decided the distribution of a cash dividend in the amount of € 3.03 per share with payment as of May 15, 2018. The General Meeting also renewed as Directors Olivier Brandicourt, Patrick Kron and Christian Mulliez and approved the appointment of Emmanuel Babeau as independent Director, for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year 2021. Following the General Meeting, the new Board of Directors is still comprised of 16 members, of whom six are women and two are Directors representing employees. A large majority of the Board's Directors is independent: Serge Weinberg*, Chairman of the Board of Directors Olivier Brandicourt, Chief Executive Officer Laurent Attal Emmanuel Babeau* Bernard Charlès* Claudie Haigneré* Patrick Kron* Fabienne Lecorvaisier* Melanie Lee* Suet-Fern Lee* Christian Mulliez Marion Palme** Carole Piwnica* Christian Senectaire** Diane Souza* Thomas Südhof* The voting results will be available on the Company's website (www.sanofi.com/AGM2018) in the coming days. The audiocast of the Annual General Shareholder Meeting is available on the Company's website (www.sanofi.com/AGM2018). During the Board of Directors session following the meeting, the Board decided to review the composition of its Committees as follows: | |||||||
| Audit Committee | Strategic Committee | Compensation Committee | |||||
| Chairwoman/ Chairman | Fabienne Lecorvaisier* | Serge Weinberg* | Patrick Kron* | ||||
| Members | Emmanuel Babeau* Christian Mulliez Diane Souza* | Laurent Attal Olivier Brandicourt Patrick Kron* | Claudie Haigneré* Christian Mulliez Diane Souza* | ||||
| Appointments & Governance Committee | Scientific Committee | ||||||
| Chairman | Serge Weinberg* | Thomas Südhof* | |||||
| Members | Claudie Haigneré* Patrick Kron* | Laurent Attal Melanie Lee* Serge Weinberg* | |||||
| (* Independent Director) (** Director representing employees) | |||||||
| About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life | |||||||
| Media Relations Contact Jack Cox Tel.: +33 (0)1 53 77 46 46 [email protected] | Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] | ||||||
Attachment
